Malignant Pleural Effusion Interventions: What Matters Most to the Patient?
Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis.
Gynecologic, Ovarian, and Cervical Cancer
GYNECOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Effect of BRCA Mutations on Ovarian Reserve After Chemotherapy
Women with BRCA 1/2 mutations have lower ovarian reserve and experience greater ovarian reserve loss after chemotherapy compared with those who are BRCA wild-type. -
Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy
Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy. -
Insurance Plans Dropping Coverage of FDA-approved BRCA Diagnostic Test
Some health care insurers have stopped covering this FDA-approved genetic test, instead limiting coverage only for cheaper, lower-quality genetic tests. -
ASCO and SGO Issue New Guidelines for Treating Ovarian Cancer
ASCO and the Society of Gynecologic Oncology jointly issued new clinical practice guidelines for the treatment of patients with ovarian cancer.
GYNECOLOGIC CANCER NEWS
CDC: Recent Decline Seen in High-Grade Cervical Lesions
Late-Line Niraparib in Advanced Ovarian Cancer: A Continuum of Clinical Benefit in Subgroups Characterized by Clinical and Molecular Biomarkers
Genetic Testing Underused in Breast, Ovarian Cancer
Chemoimmunotherapy Confers Survival Benefit in Patients With HPV16-Induced Cervical Cancer
Dendritic Cell Vaccination in Ovarian Cancer May Induce Long-Lasting Antitumor Immunity
Want to read more?
Please login or register first to view this content.
Next post in News
